

GOLDBERG MICHAEL B  
Form 4  
November 22, 2005

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**KELSO EQUITY PARTNERS V L P**

(Last) (First) (Middle)

320 PARK AVENUE,

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]**

3. Date of Earliest Transaction (Month/Day/Year)  
11/17/2005

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005		X	17,888 D	\$ 2.42	17,567,474 I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>
Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005		X	7,712 D	\$ 2.42	17,559,762 I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>
Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005		X	19,566 D	\$ 2.42	17,540,196 I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>

Edgar Filing: GOLDBERG MICHAEL B - Form 4

Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005	X	3,885	D	\$ 2.42	17,536,312	I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>
Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005	X	6,663	D	\$ 3	17,529,648	I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>
Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005	X	9,628	D	\$ 3	17,520,020	I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>
Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005	X	24,358	D	\$ 3	17,495,662	I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>
Common Stock, par value \$.01 per share <sup>(1)</sup>	11/17/2005	X	8,890	D	\$ 3.42	17,486,772	I	By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Call Option (obligation to sell)	\$ 2.42	11/17/2005		X	17,888	10/13/2005 08/26/2007	Common Stock	17,888
Call Option (obligation to sell)	\$ 2.42	11/17/2005		X	7,712	10/13/2005 08/26/2007	Common Stock	7,712

Call Option (obligation to sell)	\$ 2.42	11/17/2005	X	19,566	10/13/2005	08/26/2007	Common Stock	19,566
Call Option (obligation to sell)	\$ 2.42	11/17/2005	X	3,885	10/13/2005	08/26/2007	Common Stock	3,885
Call Option (obligation to sell)	\$ 3	11/17/2005	X	6,663	10/13/2005	08/26/2007	Common Stock	6,663
Call Option (obligation to sell)	\$ 3	11/17/2005	X	9,628	10/13/2005	08/26/2007	Common Stock	9,628
Call Option (obligation to sell)	\$ 3	11/17/2005	X	24,358	10/13/2005	08/26/2007	Common Stock	24,358
Call Option (obligation to sell)	\$ 3.42	11/17/2005	X	8,890	10/13/2005	08/26/2007	Common Stock	8,890

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KELSO EQUITY PARTNERS V L P 320 PARK AVENUE NEW YORK, NY 10022		X		
NICKELL FRANK T C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X		
BERNEY PHILIP E C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X		
BYNUM FRANK K C/O KELSO & COMPANY 320 PARK AVENUE		X		

NEW YORK, NY 10022

WALL THOMAS R IV  
 C/O KELSO & COMPANY X  
 320 PARK AVENUE  
 NEW YORK, NY 10022

GOLDBERG MICHAEL B  
 C/O KELSO & COMPANY X X  
 320 PARK AVENUE  
 NEW YORK, NY 10022

MATELICH GEORGE E  
 C/O KELSO & COMPANY X  
 320 PARK AVENUE  
 NEW YORK, NY 10022

SCHUCHERT JOSEPH S  
 C/O KELSO & COMPANY X  
 320 PARK AVENUE  
 NEW YORK, NY 10022

WAHRHAFTIG DAVID I  
 C/O KELSO & COMPANY X X  
 320 PARK AVENUE  
 NEW YORK, NY 10022

Loverro Frank J  
 320 PARK AVENUE X  
 NEW YORK, NY 10022

## Signatures

/s/James J.  
 Connors, II 11/22/2005

\*\*Signature of  
 Reporting Person Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Kelso Equity Partnes V, L.P. ("KEP V") is the designated filer.

KEP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KEP V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.

(2) Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KEP V, by virtue of his status as a general partner of the general partner of KEP V, and each individual shares investment and voting power along with the other general partners of KEP V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.

(3) Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.